Clinical trial
Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or…
NCT00002652 · University of Arkansas, Other · Completed
Key facts
| NCT number | NCT00002652 |
|---|---|
| Title | Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease |
| Official title | A PHASE II PILOT STUDY OF SURAMIN IN PREVIOUSLY TREATED PATIENTS WITH MULTIPLE MYELOMA AND PATIENTS WITH CASTLEMAN'S DISEASE |
| Lead sponsor | University of Arkansas, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Drug |
| Interventions | suramin |
| Start date | May 1, 1995 |
| Completion | Feb 1, 2004 |
| First posted | Mar 1, 2004 |
| Last update posted | Feb 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: